---
title: "ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years"
date: "2025-03-30T16:04:28.000Z"
publishedDate: "30 mars 2025"
summary: "Latest data from the Evolut Low Risk trial demonstrate a numerically lower rate of all-cause mortality or disabling stroke at five years using the Evolut (Medtronic) transcatheter aortic valve implantation (TAVI) system compared to surgery, alongside strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the 2025 American [&#8230;] The post ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/acc-25-evolut-low-risk-trial-show-comparable-rates-of-all-cause-mortality-and-stroke-with-tavi-and-surgery-at-five-years/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-03-30-acc25-evolut-low-risk-trial-shows-comparable-rates-of-all-cause-mortality-and-stroke-with-tavi-and-surgery-at-five-years"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/03/Reardon-ACC-Photo-by-%C2%A9-ACCZach-Boyden-Holmes.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/acc-25-evolut-low-risk-trial-show-comparable-rates-of-all-cause-mortality-and-stroke-with-tavi-and-surgery-at-five-years/"
---

![ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/03/Reardon-ACC-Photo-by-%C2%A9-ACCZach-Boyden-Holmes.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/acc-25-evolut-low-risk-trial-show-comparable-rates-of-all-cause-mortality-and-stroke-with-tavi-and-surgery-at-five-years/*

## L’essentiel

Latest data from the Evolut Low Risk trial demonstrate a numerically lower rate of all-cause mortality or disabling stroke at five years using the Evolut (Medtronic) transcatheter aortic valve implantation (TAVI) system compared to surgery, alongside strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the 2025 American [&#8230;] The post ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/acc-25-evolut-low-risk-trial-show-comparable-rates-of-all-cause-mortality-and-stroke-with-tavi-and-surgery-at-five-years/
